The awareness of women in terms of health is gaining significance in contemporary medical care, particularly in matters of blood cancers such as Chronic Lymphocytic Leukemia. The post Women’s Health ...

The awareness of women in terms of health is gaining significance in contemporary medical care, particularly in matters of ...

Please provide your email address to receive an email when new articles are posted on . The combination is the first all-oral, fixed duration treatment for patients with CLL and or small lymphocytic ...

Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...

The combination of ianalumab and ibrutinib led to complete responses in 38.5% of patients with CLL, allowing some to discontinue ibrutinib for up to 2 years. Ianalumab targets the BAFF receptor, ...

BRUIN CLL-313 is a randomized, open-label, global phase III study comparing the efficacy and safety of pirtobrutinib, a highly selective, noncovalent Bruton tyrosine kinase inhibitor (BTKi), against ...

Please provide your email address to receive an email when new articles are posted on . Adding ianalumab to ibrutinib allowed many patients with CLL to stop daily ibrutinib for 1 to 2 years. More than ...

IGHV status significantly influences CLL prognosis, with mutated IGHV linked to longer survival and unmutated IGHV to shorter progression-free survival. NGS enhances IGHV analysis by overcoming Sanger ...

Copyright: © 2025 The Authors. Published by Elsevier Ltd. We performed a retrospective analysis of patients with CLL registered in the Brazilian CLL Registry between ...

Pirtobrutinib was associated with a statistically significant improvement in PFS compared with bendamustine plus rituximab therapy. Topline data were announced from a phase 3 trial evaluating ...

Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with a wide range of clinical presentations that, over time, may or may not require treatment. While a minority of patients require ...